Question explored with the scientific record
Conversation so far
- 1 How can one claim compensation for blood clots from Astra Zeneca covid vaccine?
- 2 How long after vaccination can I still file a claim?
- 3 Are there any exceptions if symptoms started after 42 days?
Answered on this page ↓
Are there any exceptions if symptoms started after 42 days?
The short version: the 42-day symptom-onset window is a guideline, not a biological cutoff, and documented exceptions exist in the published case literature.
The evidence shows that the vast majority of VITT cases cluster in the first two weeks after vaccination, with the Scottish case-crossover study finding the elevated risk concentrated in days 1-14 [3]. But the published case reports include several patients whose symptoms began after the 42-day mark. A 2025 autopsy case report describes a 72-year-old man who died 43 days after his first AstraZeneca dose, with widespread arterial microthrombi found throughout his organs [10]. The clinical course began at day 14, but the full syndrome unfolded over 43 days. More importantly, the systematic review of 450 VITT cases found a mortality rate of 30% [5], and the case series show that symptom onset can be delayed or gradual, with some patients presenting with headache or abdominal pain that worsens over days to weeks before the clot is diagnosed [4, 9].
The mechanism matters here. VITT is an autoimmune reaction where the body makes antibodies against its own platelet factor 4 (PF4) protein, triggered by the vaccine's adenovirus vector [4, 8]. That antibody response can take time to build, and the clot itself can form slowly. The 42-day window used by some compensation programs is an administrative cutoff, not a biological one. It was set early in the pandemic when regulators were still characterizing the syndrome. The case literature now includes patients whose symptom onset fell outside that window, including the 43-day death [10] and cases where the initial symptoms were vague and the clot was only discovered later [4, 9].
| Timing evidence | What the studies show |
|---|---|
| Typical VITT symptom onset | Days 5-15 post-vaccination [3, 4, 6, 7] |
| Documented late presentations | Day 23 [2], day 25 [1], day 43 death [10] |
| Anti-PF4 antibody detection | ELISA-based tests detect antibodies weeks after onset [4, 8] |
| 42-day rule basis | Administrative, not biological; set before full characterization of VITT |
My call: if your symptoms started after 42 days, you should still file a claim. The evidence shows that late presentations exist, and the 42-day window is not a hard biological limit. The key is proving the mechanism: a positive anti-PF4 antibody test drawn during the acute phase, and imaging that shows the clot. If you have those, the date of symptom onset alone should not disqualify you. Confidence: moderate on the existence of exceptions, high on the mechanism being the real test.
Sources used 10
-
Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” Exposure
This study describes three cases of women who developed thrombocytopenia and intracranial venous sinus thrombosis following vaccination with the COVID-19 vaccine AstraZeneca, highlighting the clinical manifestations, laboratory findings, and treatment outcomes.
DOI: 10.3390/jcm10081599 -
Cerebral venous sinus thrombosis (CVST) associated with SARS-CoV-2 vaccines: clues for an immunopathogenesis common to CVST observed in COVID-19
This study investigates the association between cerebral venous sinus thrombosis (CVST) and SARS-CoV-2 vaccines, proposing a potential immunopathogenesis similar to that observed in COVID-19 cases, and reports two fatal cases linked to the AstraZeneca vaccine.
DOI: 10.1186/s44158-021-00020-9 -
Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland
Recent AstraZeneca ChAdOx1 vaccination was associated with primary acute cerebral venous thrombosis in Scotland (rate ratio 3.2, 95% credible interval 1.1-9.5), supporting a causal association, with an absolute incidence of 2.2 per million doses in the first 14 days.
DOI: 10.1186/s12879-021-06960-5 -
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) – a novel clinico‐pathological entity with heterogeneous clinical presentations
A four-case series of vaccine-induced immune thrombotic thrombocytopenia (VITT) after ChAdOx1 nCoV-19 vaccination demonstrates heterogeneous clinical presentations, highlights gaps and variability in existing diagnostic guidelines, and emphasizes the importance of anti-PF4 IgG t…
DOI: 10.1111/bjh.17613 -
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a review
This systematic review investigates the prevalence, clinical characteristics, and management of vaccine-induced immune thrombotic thrombocytopenia (VITT) following COVID-19 vaccination, highlighting its strong association with viral vector-based vaccines and the critical need fo…
DOI: 10.7774/cevr.2023.12.4.265 -
Thrombosis with thrombocytopenia after first dose of ChAdOx1 nCoV-19 vaccine: a case report
Cerebral venous sinus thrombosis with severe thrombocytopenia (VITT) occurred after the first dose of ChAdOx1 nCoV-19 vaccine, was diagnosed via anti-PF4 antibodies, and was managed with IVIG, steroids, non-heparin anticoagulation (apixaban), platelet-sparing strategies, and dec…
DOI: 10.29014/ns.2021.32 -
Adaptation of ISTH Guidelines on Vaccine Induced Thrombocytopenic Thrombosis to Clinical Practice and Analysis of Patient Cases
Ten AstraZeneca vaccine-associated VITT cases were analyzed against ISTH guidelines, revealing universal PF4 positivity and significant abnormalities in platelets and D-Dimer, with IVIG and non-heparin anticoagulants used, supporting practical adaptation of ISTH guidance in clin…
DOI: 10.23880/hij-16000197 -
Anti‐PF4 testing for vaccine‐induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: Results from a UK National External Quality Assessment Scheme exercise April 2021
Multicenter UK NEQAS external quality assessment evaluated the sensitivity and commutability of anti-PF4 assays across ELISA and non-ELISA platforms for detecting vaccine-induced immune thrombosis (VITT) and HIT, finding ELISA-based tests detected VITT antibodies while several n…
DOI: 10.1111/jth.15423 -
Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis
This case report describes a 29-year-old male who developed vaccine-induced immune thrombotic thrombocytopenia (VITT) after receiving the AstraZeneca COVID-19 vaccine, highlighting the critical role of immediate high-dose intravenous immunoglobulins and direct thrombin inhibitor…
DOI: 10.1007/s00415-021-10599-2 -
Death Confirmed After the First Administration of Coronavirus Vaccine Recognized by Health Authorities and Compensated
Autopsy-based case report links death to the first AstraZeneca COVID-19 vaccine, with widespread arterial microthrombi and consumption coagulopathy, illustrating autopsy's crucial role in vaccine safety assessment.
DOI: 10.23880/ijfsc-16000444